Indeed, tumour-targeted IL-2 has been shown to be capable of amplifying CD8+ T cells after IL-12 vaccination and enhancing MHC I-mediated killing in a murine model of neuroblastoma metastasis (Lode et al, 1999). The gene discussed is CD8A; the disease is neuroblastoma.